Latest News from: Ludwig Cancer Research

Filters close
Newswise: Ludwig Lausanne Study Identifies Potential Combination Therapy for Testing in Deadly Brain Cancer
Released: 20-Sep-2022 11:40 AM EDT
Ludwig Lausanne Study Identifies Potential Combination Therapy for Testing in Deadly Brain Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).

Newswise: Pat Morin Appointed Deputy Scientific Director of the Ludwig Institute for Cancer Research
Released: 12-Jul-2022 10:05 AM EDT
Pat Morin Appointed Deputy Scientific Director of the Ludwig Institute for Cancer Research
Ludwig Cancer Research

Ludwig Cancer Research extends a warm welcome to Pat Morin, who has been appointed deputy scientific director of the Ludwig Institute for Cancer Research.

Newswise: Ludwig MSK Study Modeling Tumor Evolution Reveals a Vulnerability for Cancer Prevention and Therapy
Released: 11-May-2022 11:05 AM EDT
Ludwig MSK Study Modeling Tumor Evolution Reveals a Vulnerability for Cancer Prevention and Therapy
Ludwig Cancer Research

Though the mutations accumulated by cancer cells occur more or less randomly, certain regions of genes essential to cancer growth appear to be more frequently mutated than others in established tumors.

Released: 4-Apr-2022 12:05 PM EDT
Ludwig Cancer Research Scientists to Present Advances in Cancer Research at 2022 AACR Annual Meeting
Ludwig Cancer Research

Ludwig Cancer Research released today the full scope of research to be presented by Ludwig-affiliated scientists at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which will be held online and in person at the Ernest N. Morial Convention Center, in New Orleans, Louisiana, from April 8 to April 13.

Newswise: Ludwig Stanford Study Solves Long-Sought Protein Structure, Shows How Mutation Drives Blood Cancers
Released: 10-Mar-2022 2:25 PM EST
Ludwig Stanford Study Solves Long-Sought Protein Structure, Shows How Mutation Drives Blood Cancers
Ludwig Cancer Research

Researchers led by Christopher Garcia of the Ludwig Center at Stanford University have solved the long-sought structure of a large signaling protein involved in responses to infection, inflammation, the generation of immune cells and—when dysregulated by mutation—the emergence of blood cancers known as myeloproliferative neoplasms.

Newswise: Ludwig Princeton Preclinical Study Shows Ketogenic Diet Could Enhance Pancreatic Cancer Therapy
Released: 11-Feb-2022 11:40 AM EST
Ludwig Princeton Preclinical Study Shows Ketogenic Diet Could Enhance Pancreatic Cancer Therapy
Ludwig Cancer Research

A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.

Newswise: Ludwig Cancer Research Study Identifies Potential Vulnerability in Drug-Resistant Neuroblastoma
Released: 7-Feb-2022 12:45 PM EST
Ludwig Cancer Research Study Identifies Potential Vulnerability in Drug-Resistant Neuroblastoma
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

Released: 15-Nov-2021 11:00 AM EST
Ludwig Lausanne Team Devises a Method to Selectively Grow Tumor-Targeting T Cells for Cancer Therapy
Ludwig Cancer Research

A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens—small fragments of randomly mutated proteins that are typically unique to a patient’s cancer—and destroy the tumors that express them.

Newswise: CoukosBanner.png
Released: 5-Nov-2021 4:45 PM EDT
Ludwig Cancer Research Study Identifies Cellular Interactions Essential to the Immune Attack on Ovarian Tumors
Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered a cellular interaction that is essential to the ability of the immune system’s cytotoxic T lymphocytes to destroy ovarian tumors and shown that its engagement could help determine the efficacy of checkpoint blockade immunotherapy in a variety of cancers.

Newswise: Ludwig Lausanne Study Shows How Tumors Turn Immune Cells Into Enablers of Their Growth
Released: 25-Oct-2021 12:00 PM EDT
Ludwig Lausanne Study Shows How Tumors Turn Immune Cells Into Enablers of Their Growth
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a means by which cancer cells engineer the conversion of immune cells known as macrophages from destroyers of tumors to supporters of their growth and survival.

Newswise: Ludwig Lausanne Study Identifies Potential Combination Therapy for Brain Metastases of Breast Cancer
18-Oct-2021 11:00 AM EDT
Ludwig Lausanne Study Identifies Potential Combination Therapy for Brain Metastases of Breast Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study has identified and preclinically validated combination treatments for the brain metastases of breast cancer, a common and typically lethal manifestation of the malignancy.

Newswise: CoukosBanner.png
Released: 9-Sep-2021 3:05 PM EDT
Ludwig Lausanne Researchers Show a Little Radiation Goes a Long Way in Heating Up Cold Tumors
Ludwig Cancer Research

A Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called “cold” tumors that are nearly devoid of immune cells—and therefore unresponsive to immunotherapy—can be turned “hot” with extremely low doses of radiation and the rational use of existing therapies.

Released: 4-Aug-2021 9:00 AM EDT
Ludwig Cancer Research Welcomes Mikaël Pittet to Ludwig Lausanne
Ludwig Cancer Research

It is with great pleasure that we announce the appointment of Mikaël Pittet as a full Member of the Lausanne Branch of the Ludwig Institute for Cancer Research.

Released: 15-Jul-2021 6:30 PM EDT
Ludwig Cancer Research Study Reveals Even Transient Chromosomal Errors Can Initiate Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study has found that inducing random chromosome instability (CIN) events in mice for as little as one week is enough to trigger harmful chromosomal patterns in cells that spur the formation of tumors.

10-Jun-2021 11:05 AM EDT
Ludwig Cancer Research Study Shows How Certain Macrophages Dampen Anti-Tumor Immunity
Ludwig Cancer Research

A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system’s cancer-killing CD8+ T cells. Reported in the current issue of Cancer Cell and led by Ludwig investigators Taha Merghoub and Jedd Wolchok at Memorial Sloan Kettering (MSK) and Charles Rudin of MSK, the study shows that cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), a molecule that they surprisingly found on the surface of highly activated, cytotoxic and proliferative CD8+ T-cells.

8-Jun-2021 2:00 PM EDT
Ludwig Cancer Research Study Employs Novel Drug Screen to Identify a Potential Individualized Triple-Negative Breast Cancer Therapy
Ludwig Cancer Research

A study conducted by researchers at the Ludwig Center at Harvard has demonstrated how a drug screening method known as dynamic BH3 profiling can be used to quickly identify potentially effective combinations of existing drugs for personalized cancer therapy.

Released: 24-May-2021 11:15 AM EDT
Ludwig Cancer Research Study Discovers How to Revive Potent but Inert Anti-Cancer Immune Cells for Therapy
Ludwig Cancer Research

A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy. Led by Ludwig Lausanne’s Ping-Chih Ho and Li Tang of the École Polytechnique Fédérale de Lausanne, the study describes how an immune factor known as interleukin-10 orchestrates the functional revival of “terminally exhausted” tumor-infiltrating T lymphocytes (TILs), which have so far proved impervious to stimulation by immunotherapies. It also demonstrates that the factor, when applied in combination with cell therapies, can eliminate tumors in mouse models of melanoma and colon cancer. The findings are reported in the current issue of Nature Immunology.

Released: 28-Apr-2021 9:15 AM EDT
Ludwig Cancer Research Study Shows Pancreatic Cancer Cells Hit Reverse to Advance in Malignancy
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert—or “de-differentiate”—to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.

Released: 13-Apr-2021 8:30 AM EDT
Ludwig Cancer Research Opens New Branch Dedicated to Cancer Metabolism at Princeton University
Ludwig Cancer Research

Ludwig Cancer Research is proud to announce on its 50th anniversary the launch of the newest Branch of the Ludwig Institute for Cancer Research.

Released: 15-Feb-2021 11:00 AM EST
Ludwig Cancer Research Study Uncovers Metabolic Vulnerability in Suppressive Immune Cells That May Be Targeted for Cancer Immunotherapy
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors.

Released: 26-Jan-2021 11:00 AM EST
Ludwig Cancer Research Study Reveals How Certain Gut Bacteria Compromise Radiotherapy
Ludwig Cancer Research

A study led by Ludwig Chicago Co-director Ralph Weichselbaum and Yang-Xin Fu of the University of Texas Southwestern Medical Center has shown how bacteria in the gut can dull the efficacy of radiotherapy, a treatment received by about half of all cancer patients.

Released: 24-Dec-2020 8:00 AM EST
Ludwig Cancer Research Study Reveals How Circular ecDNA is Generated and Drives Drug Resistance in Cancer
Ludwig Cancer Research

Researchers led by Ludwig San Diego Member Don Cleveland and Peter Campbell of the Sanger Center have solved the mystery of how free-floating circular DNA fragments, which are almost exclusively found in cancer cells, drive gene amplification to generate drug resistance in cancer.

Released: 14-Nov-2020 9:30 AM EST
Ludwig Lausanne Receives Team Science Award from the Society for Immunotherapy of Cancer
Ludwig Cancer Research

Ludwig Cancer Research is proud to announce that the Lausanne Branch of the Ludwig Institute for Cancer Research has received a Team Science Award from the Society for Immunotherapy of Cancer (SITC).

Released: 6-Nov-2020 10:00 AM EST
A Better Test for the Tumor-Targeting of CAR-T Therapies
Ludwig Cancer Research

Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system’s T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment.

Released: 5-Oct-2020 11:00 AM EDT
Ludwig Study Finds a Common Nutritional Supplement Might Boost the Effects of Cancer Immunotherapy
Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered a mechanism by which the tumor’s harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response.

Released: 24-Aug-2020 3:55 PM EDT
Ludwig Chicago Study Identifies a Novel Drug Target for the Control of Cancer Metastasis
Ludwig Cancer Research

Researchers led by Ludwig Chicago Co-director Ralph Weichselbaum and Ronald Rock of the University of Chicago have identified in preclinical studies a potential drug target for curtailing cancer metastasis.

Released: 27-Jul-2020 4:35 PM EDT
Ludwig San Diego Study Identifies Deadly Genetic Synergy in Cancer Cells and Shows it Might Be Exploited for Therapy
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a new instance in which the simultaneous mutation of two nonessential genes—neither of which is on its own vital to cell survival—can cause cancer cell death.

Released: 15-Jul-2020 3:20 PM EDT
Ludwig Cancer Research Study Finds Reprogramming of Immune Cells Enhances Effects of Radiotherapy in Preclinical Models of Brain Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.

Released: 14-Jul-2020 9:00 AM EDT
Juanita L. Merchant Appointed to the Ludwig Institute’s Scientific Advisory Committee
Ludwig Cancer Research

Ludwig Cancer Research welcomes Juanita L. Merchant to the Scientific Advisory Committee of the Ludwig Institute for Cancer Research.

Released: 1-Jul-2020 9:00 AM EDT
Epigenetics Researcher Yang Shi Appointed Member of Ludwig Oxford
Ludwig Cancer Research

It is with great pleasure that Ludwig Cancer Research announces the appointment of Yang Shi as Member of the Oxford Branch of the Ludwig Institute for Cancer Research.

Released: 28-May-2020 12:15 PM EDT
Ludwig Lausanne Study Charts the Immune Landscape of Multiple Brain Cancers
Ludwig Cancer Research

A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.

Released: 29-Apr-2020 11:25 AM EDT
Ludwig Oxford Director Xin Lu Elected to the Royal Society
Ludwig Cancer Research

Ludwig Cancer Research extends its congratulations to Xin Lu, director of the Oxford Branch of the Ludwig Institute for Cancer Research, on her election to the Fellowship of the Royal Society.

   
Released: 15-Apr-2020 11:00 AM EDT
Ludwig MSK Study Reveals Bile Metabolite of Gut Microbes Boosts Immune Cells
Ludwig Cancer Research

A Ludwig Cancer Research study has discovered a novel means by which bacterial colonies in the small intestine support the generation of regulatory T cells—immune cells that suppress autoimmune reactions and inflammation.

Released: 17-Feb-2020 11:00 AM EST
Targeting Turncoat Immune Cells to Treat Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study has identified a mechanism by which regulatory T cells, which suppress immune responses, adapt their metabolism to thrive in the harsh microenvironment of the tumor.

Released: 3-Feb-2020 11:20 AM EST
Building a Safer CAR-T Therapy
Ludwig Cancer Research

A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell—a family of promising immunotherapies for cancer—that can be switched on and off on demand.

Released: 31-Jan-2020 9:00 AM EST
Robert Schreiber Joins the Ludwig Institute's Scientific Advisory Committee
Ludwig Cancer Research

Ludwig Cancer Research extends a warm welcome to Robert Schreiber, the newest member of the Scientific Advisory Committee of the Ludwig Institute for Cancer Research.

Released: 14-Jan-2020 3:00 AM EST
Douglas Hanahan Appointed Distinguished Scholar of the Ludwig Institute for Cancer Research
Ludwig Cancer Research

Ludwig Cancer Research is pleased to announce the appointment of Douglas Hanahan as a Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research.

Released: 9-Jan-2020 3:00 AM EST
Ping-Chih Ho Appointed Associate Member of Ludwig Institute for Cancer Research
Ludwig Cancer Research

Ludwig Cancer Research congratulates Ping-Chih Ho on his appointment as Associate Member at the Lausanne Branch of the Ludwig Institute for Cancer Research.

Released: 13-Nov-2019 6:00 AM EST
Ludwig Lausanne’s Ping-Chih Ho Named an EMBO Young Investigator
Ludwig Cancer Research

Ludwig Cancer Research congratulates Ping-Chih Ho on his selection by the European Molecular Biology Association (EMBO) as a member of its Young Investigator Programme.

Released: 14-Oct-2019 12:00 PM EDT
Ludwig Researchers Develop Machine Learning Tool to Refine Personalized Immunotherapy
Ludwig Cancer Research

Ludwig Cancer Research scientists have developed a new and more accurate method to identify the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents.

Released: 7-Oct-2019 4:30 PM EDT
Ludwig Oxford’s Sir Peter Ratcliffe Wins Nobel Prize
Ludwig Cancer Research

Ludwig Cancer Research congratulates Peter Ratcliffe on his receipt of the 2019 Nobel Prize for Physiology or Medicine. He was recognized by the Nobel Committee for his landmark discoveries on the mechanisms by which mammalian cells sense and respond to the availability of oxygen.

Released: 19-Sep-2019 9:00 AM EDT
Alexandra Johnson Appointed to the Board of the Ludwig Institute for Cancer Research
Ludwig Cancer Research

Ludwig Cancer Research welcomes Alexandra Johnson to the Board of Directors of the Ludwig Institute for Cancer Research.

Released: 22-Aug-2019 11:00 AM EDT
Ludwig Study Identifies an Achilles Heel of Many Types of Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered a novel vulnerability in tumors that are driven by a common cancer gene known as MYC. Such cancers, it found, are highly dependent on the cell’s machinery for making fats and other lipids.

Released: 30-Jul-2019 9:40 AM EDT
Leading Oncologists and Nutritionists Pinpoint Key Areas to Catalyze Nutrition-based Cancer Prevention Research and Interventions
Ludwig Cancer Research

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship between nutrition and cancer.

Released: 5-Jul-2019 9:00 AM EDT
Ludwig Study Uncovers Novel Cellular Oxygen Sensor
Ludwig Cancer Research

A Ludwig Cancer Research study led by Peter Ratcliffe and colleagues has discovered a previously overlooked oxygen sensor in animal cells that functions very much like one used by plants.

Released: 10-Jun-2019 11:00 AM EDT
Molecular Chatter Makes for a “Hot Tumor”
Ludwig Cancer Research

A Ludwig Cancer Research study has deciphered a complex molecular conversation between cancer and immune cells that is key to orchestrating the successful invasion of tumors by T cells that kill cancer cells.

Released: 24-Apr-2019 1:30 PM EDT
Studying Cell Lineage in Tumors Reveals Targetable Vulnerabilities
Ludwig Cancer Research

To explain a person’s actions in the present, it sometimes helps to understand their past, including where they come from and how they were raised. This is also true of tumors. Delving into a tumor’s cellular lineage, a Ludwig Cancer Research study shows, can reveal weaknesses to target for customized therapies.

Released: 21-Mar-2019 9:00 AM EDT
Ludwig Researchers Present Advances in CAR T Cell Therapeutics, Precision Medicine and Cancer Diagnostics at AACR Annual Meeting 2019
Ludwig Cancer Research

Ludwig Cancer Research released today the full breadth of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Ga., March 29 – April 3, 2019. Research conducted by more than 75 Ludwig scientists will be shared in plenary sessions, major symposiums, education sessions, poster sessions and more.

27-Feb-2019 11:05 AM EST
An Atlas of an Aggressive Leukemia
Ludwig Cancer Research

A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed “atlas of cell states” for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Released: 25-Feb-2019 11:00 AM EST
A New Sequencing Method to Detect DNA Modifications of Relevance to Cancer
Ludwig Cancer Research

Ludwig Cancer Research scientists report in the current issue of Nature Biotechnology a new and improved method to detect chemical modifications to DNA. These modifications—or “epigenetic” marks—help control gene expression and their aberrant distribution across the genome contributes to cancer progression and resistance to therapy.


Showing results

150 of 172

close
0.3917